Largely Unchanged Annual Incidence and Overall Survival of Pleural Mesothelioma in the USA.
Journal
World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
pubmed:
21
8
2019
medline:
16
7
2020
entrez:
21
8
2019
Statut:
ppublish
Résumé
Projections based on regulations curtailing asbestos use in the USA suggest that peak incidence of pleural mesothelioma would occur between 2000 and 2005 and then decline. We analyzed the National Cancer Database (NCDB) to assess current trends in disease incidence, patient demographics, cancer treatment, and survival. The NCDB was queried to identify patients diagnosed with pleural mesothelioma from 2004 through 2014. Clinical and pathologic characteristics, treatments, and survival were analyzed. Risk factors for death were identified by multivariable Cox regression. A total of 20,988 patients with pleural mesothelioma were reported to the NCDB. The number of cases per year increased from 1783 to 1961, accounting for roughly 0.3% of all reported cancers each year. The proportion of elderly patients increased from 75 to 80%, but distribution by sex remained constant (20% female). The proportion of patients undergoing treatment increased from 34 to 54%. One-year survival increased from 37 to 47% and 3-year survival from 9 to 15% (p < 0.001). Factors associated with improved survival included younger age, female sex, epithelioid histology, treatment in an academic center, health insurance, higher income, and multimodality therapy. The annual incidence of mesothelioma has not declined this century and remains stable. Reporting of histologic and clinical staging has improved. National trends suggest that survival is slowly increasing despite an aging cohort. Multimodal therapy and treatment at academic centers are modifiable risk factors associated with improved survival.
Sections du résumé
BACKGROUND
Projections based on regulations curtailing asbestos use in the USA suggest that peak incidence of pleural mesothelioma would occur between 2000 and 2005 and then decline. We analyzed the National Cancer Database (NCDB) to assess current trends in disease incidence, patient demographics, cancer treatment, and survival.
METHODS
The NCDB was queried to identify patients diagnosed with pleural mesothelioma from 2004 through 2014. Clinical and pathologic characteristics, treatments, and survival were analyzed. Risk factors for death were identified by multivariable Cox regression.
RESULTS
A total of 20,988 patients with pleural mesothelioma were reported to the NCDB. The number of cases per year increased from 1783 to 1961, accounting for roughly 0.3% of all reported cancers each year. The proportion of elderly patients increased from 75 to 80%, but distribution by sex remained constant (20% female). The proportion of patients undergoing treatment increased from 34 to 54%. One-year survival increased from 37 to 47% and 3-year survival from 9 to 15% (p < 0.001). Factors associated with improved survival included younger age, female sex, epithelioid histology, treatment in an academic center, health insurance, higher income, and multimodality therapy.
CONCLUSIONS
The annual incidence of mesothelioma has not declined this century and remains stable. Reporting of histologic and clinical staging has improved. National trends suggest that survival is slowly increasing despite an aging cohort. Multimodal therapy and treatment at academic centers are modifiable risk factors associated with improved survival.
Identifiants
pubmed: 31428834
doi: 10.1007/s00268-019-05132-6
pii: 10.1007/s00268-019-05132-6
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3239-3247Subventions
Organisme : NHLBI NIH HHS
ID : U01 HL088955
Pays : United States
Commentaires et corrections
Type : ErratumIn
Type : CommentIn
Références
Med J Aust. 2011 Sep 5;195(5):271-4
pubmed: 21895596
N Engl J Med. 1965 Mar 18;272:560-5
pubmed: 14248731
J Thorac Cardiovasc Surg. 2008 Mar;135(3):620-6, 626.e1-3
pubmed: 18329481
Med Leg J. 2015 Mar;83(1):26-8
pubmed: 24973234
Cancer. 1997 Dec 15;80(12):2296-304
pubmed: 9404707
Arch Pathol Lab Med. 2018 Jan;142(1):89-108
pubmed: 28686500
Clin Chem Lab Med. 2011 Jan;49(1):5-7
pubmed: 21158701
Ann Thorac Surg. 2014 Sep;98(3):1020-4
pubmed: 24928677
Environ Sci Technol. 2007 Mar 15;41(6):1808-9
pubmed: 17410766
Public Health Rep. 2006 Sep-Oct;121(5):609-14
pubmed: 16972515
Am J Ind Med. 2005 May;47(5):458-62
pubmed: 15828068
Cancer Res. 2010 Jul 15;70(14):5686-94
pubmed: 20587528
Ann Thorac Surg. 2010 Sep;90(3):949-56; discussion 956
pubmed: 20732523
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Eur J Surg Oncol. 2017 Apr;43(4):788-795
pubmed: 28131669
Cancer Res. 2016 Jan 15;76(2):319-28
pubmed: 26554828
JAMA. 1964 Apr 6;188:22-6
pubmed: 14107207
J Occup Environ Med. 2005 Aug;47(8):817-25
pubmed: 16093931
J Thorac Oncol. 2007 Oct;2(10):957-65
pubmed: 17909360
Lung Cancer. 2004 Aug;45 Suppl 1:S77-9
pubmed: 15261439
Disaster Med Public Health Prep. 2011 Sep;5 Suppl 2:S189-96
pubmed: 21908698
Semin Thorac Cardiovasc Surg. 2009 Summer;21(2):105-10
pubmed: 19822281
J Thorac Oncol. 2018 Nov;13(11):1655-1667
pubmed: 30266660
Ann Thorac Surg. 2018 Feb;105(2):432-437
pubmed: 29223422
Ann Surg Oncol. 2010 Jan;17(1):4-7
pubmed: 19847564
Med Anthropol. 2011 Jan;30(1):30-55
pubmed: 21218355
Br J Ind Med. 1960 Oct;17:260-71
pubmed: 13782506
New Solut. 2015 Aug;25(2):172-88
pubmed: 25910492
Lung Cancer. 2013 May;80(2):153-8
pubmed: 23415607
Environ Health Prev Med. 2008 Mar;13(2):60-4
pubmed: 19568882
Environ Health Perspect. 2008 Jun;116(6):723-6
pubmed: 18560526